Oxford BioDynamics Limited has entered into a Technology and Evaluation Agreement with a second major US Pharmaceutical Company to identify EpiSwitchTM signatures using their EpiSwitchTM Biomarker discovery platform in order to differentiate Diffuse Large B-cell Lymphoma (DLBCL) prognostic subgroups.